Workflow
Cachet(002462)
icon
Search documents
嘉事堂:2023年度独立董事述职报告(梁雨)
2024-04-28 08:16
嘉事堂药业股份有限公司 2023 年度独立董事述职报告 根据《上市公司独立董事管理办法》和《公司章程》的规定,作为嘉事堂药 业股份有限公司(以下简称"嘉事堂"或"公司")第七届董事会独立董事,现 将本人本年度履行独立董事职责情况述职如下: 本人在每次会议召开之前,均主动了解做出决策所需要的情况和资料,了解 公司整体的经营情况。在会议召开期间,详细听取公司管理层就有关情况的说明, 认真审议每项议案,积极参与讨论并提出合理化建议,并以谨慎的态度在会议上 行使表决权。 报告期内各次董事会、专门委员会会议审议的相关议案均未损害全体股东的 利益,特别是中小股东的利益,因此本人均投出赞成票,没有反对、弃权的情况。 2023 年,本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》 《深圳证券交易所股票上市规则》等法律、法规、规范性文件及《公司章程》、 《独立董事工作制度》等内部制度的规定和要求,勤勉尽责地履行独立董事的职 责和义务,审慎认真地行使公司和股东赋予的权利,积极参加股东大会、董事会 及专门委员会会议,维护公司整体利益,维护全体股东尤其是中小股东的合法权 益,并在深入了解公司情况的基础上,运用专业知识和经 ...
嘉事堂:关于2023年度利润分配预案的公告
2024-04-28 08:16
股票代码:002462 股票简称:嘉事堂 公告编号:2024-16 嘉事堂药业股份有限公司 关于 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整,没有虚假记载、误导性陈述或重大遗漏。 嘉事堂药业股份有限公司(以下简称"嘉事堂"或"公司")第七届董事会 第九次会议于 2024 年 4 月 26 日审议通过了公司关于 2023 年度利润分配预案的 议案,尚需提交公司 2023 年度股东大会审议。现将情况披露如下: 本次利润分配预案,严格遵循《公司法》《证券法》等法律法规和中国证监 会《上市公司监管指引第 3 号——上市公司现金分红》以及《公司章程》的相关 规定,具备合法性、合规性。 3、利润分配预案与公司成长性的匹配性 基于公司实际情况和结合公司未来的发展前景和战略规划,在保证公司正常 经营和长远发展的前提下,提出了本次利润分配的预案。该分配预案兼顾了公司 股东的当期利益和长期利益,充分考虑了广大投资者的合理诉求,与公司经营业 绩及未来发展相匹配,不会造成公司流动资金短缺或其他不良影响,符合公司的 发展规划。公司本次现金分红水平与所处行业上市公司平均水平不存在重大差异 ...
嘉事堂(002462) - 2023 Q4 - 年度财报
2024-04-28 08:16
Financial Performance - The company's operating revenue for 2023 was CNY 29,996,240,361.78, representing a 14.40% increase compared to CNY 26,219,790,244.85 in 2022[17] - The net profit attributable to shareholders decreased by 15.79% to CNY 250,060,041.68 from CNY 296,935,789.27 in the previous year[17] - The net profit after deducting non-recurring gains and losses was CNY 239,475,788.49, down 15.78% from CNY 284,354,722.16 in 2022[17] - The basic earnings per share fell to CNY 0.86, a decrease of 15.69% from CNY 1.02 in the previous year[17] - The total assets at the end of 2023 were CNY 17,120,851,592.43, an increase of 3.41% from CNY 16,556,608,348.72 at the end of 2022[17] - The net assets attributable to shareholders increased by 3.98% to CNY 4,240,525,334.01 from CNY 4,078,022,999.53 in 2022[17] - The cash flow from operating activities showed a significant improvement, reaching CNY 1,595,439,529.42, compared to a negative cash flow of CNY -163,448,296.26 in the previous year, marking a 1,076.11% increase[17] - The weighted average return on equity decreased to 6.03% from 7.49% in the previous year[17] - The company reported a quarterly revenue of CNY 8,208,583,575.92 in Q4 2023, contributing to a total annual revenue of nearly CNY 30 billion[22] - In 2023, the company achieved a revenue of CNY 29.996 billion and a net profit of CNY 377 million, demonstrating resilience against industry changes and price reductions[30] Market Position and Operations - The pharmaceutical segment serves over 300 hospitals in Beijing, achieving a coverage rate of 99%[30] - The company ranks 12th in the national pharmaceutical commercial industry as of 2022, indicating a strong market position[29] - The medical device segment has established sales channels with over 2,000 hospitals across key regions, including the Yangtze River Delta and the Greater Bay Area[30] - The average annual growth rate of national pharmaceutical sales from 2020 to 2023 was 13.94%, reflecting a stable market[28] - The company has over 2,000 upstream production partners, with more than 40,000 product specifications currently managed[32] - The logistics segment supports public health emergency material reserves for Beijing, ensuring essential drug distribution[31] - The company has implemented innovative business models, expanding from drug distribution to medical device supply chain services and traditional Chinese medicine[32] Revenue Breakdown - Total revenue for 2023 reached ¥29,996,240,361, representing a year-on-year increase of 14.40% compared to ¥26,219,790,244 in 2022[36] - Pharmaceutical wholesale contributed ¥28,330,191,776, accounting for 94.45% of total revenue, with a year-on-year growth of 2.31%[36] - Revenue from Beijing decreased by 3.03% to ¥11,156,013,238, while other regions saw an increase of 3.03% to ¥18,840,227,123[37] - The gross profit margin for pharmaceutical wholesale was 6.62%, down by 0.97% from the previous year[38] Investments and Acquisitions - The company acquired 100% equity of Yaan Jiashirongjin Pharmaceutical Co., Ltd. for ¥500,000 on March 31, 2023[42] - The company established four new subsidiaries in 2023, focusing on brand management and medical device sales[43] - The company completed an acquisition of a smaller biotech firm for 500 million RMB to enhance its product pipeline[88] Cash Flow and Financial Management - The net cash flow from operating activities increased by 1,076.11% year-on-year, reaching CNY 1,595,439,529.42, primarily due to improved accounts receivable management and increased cash collection[46] - The total net increase in cash and cash equivalents was CNY 778,696,997.05, a significant increase of 255.21% compared to the previous year[49] - The company’s investment activities resulted in a net cash outflow of CNY 185,250,468.20, a decrease of 5.59% year-on-year[46] - The company’s financial expenses decreased by 19.61% to CNY 143,870,481.10 due to reduced external financing costs[48] Governance and Compliance - The company has established effective performance evaluation and incentive mechanisms for its management[77] - The company is committed to strengthening party leadership and governance within its operational framework[67] - The company maintains a fully independent business system, with no reliance on related transactions with the largest shareholder, ensuring complete market-oriented operational capability[81] - The company has established a complete and independent financial accounting system, complying with the requirements of the Accounting Standards for Enterprises[83] - The company emphasizes communication and cooperation with stakeholders to balance interests among shareholders, employees, and society[80] Employee Management and Compensation - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 984.26 million[106] - The deferred performance compensation for 2021 paid in 2023 totaled CNY 81.39 million, while the performance compensation for 2022 amounted to CNY 106.86 million[105] - The company has a structured remuneration management system for senior management, approved by the board of directors[103] - The total number of employees at the end of the reporting period is 2,357, with 984 retirees[113] Corporate Social Responsibility - The company actively participated in rural revitalization efforts in 2023, aligning with national policies and demonstrating corporate social responsibility[166] - The company donated over RMB 150,000 worth of 14,085 boxes of epidemic prevention drugs to support designated poverty alleviation counties during the Spring Festival[170] - The company provided pharmaceutical delivery services worth approximately RMB 83.8982 million to thousands of pharmacies and clinics in remote areas of Southwest China[170] Risk Management - The company emphasizes risk management and compliance, integrating risk control into all operational aspects[67] - The company conducts regular risk assessments and implements internal control measures to ensure business transaction risks are manageable, maintaining operational safety[128] - The company has established strict management controls for major investments, ensuring compliance with legal and procedural requirements to mitigate investment risks[133] Future Outlook - The company provided a revenue guidance for 2024, expecting a growth rate of 10% to 12%[88] - The company aims to enhance its market share in high-value consumables and explore new business avenues while focusing on high-quality development[67] - Market expansion plans include entering two new international markets by the end of 2024, targeting a 5% market share in each[88]
嘉事堂:内部控制审计报告
2024-04-28 08:16
嘉事堂药业股份有限公司 内部控制审计报告 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化可 能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根据内部控制审计结果推 测未来内部控制的有效性具有一定风险。 内部控制审计报告 安永华明(2024)专字第61555536_A01号 嘉事堂药业股份有限公司 嘉事堂药业股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了嘉事 堂药业股份有限公司 2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》的 规定,建立健全和有效实施内部控制,并评价其有效性是嘉事堂药业股份有限公司董事会的责 任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见,并 对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 2023年度 四、财务报告内部控制审计意见 我们认为,嘉事堂药业股份有限公司于 2023 年 12 月 31 ...
嘉事堂(002462) - 2024 Q1 - 季度财报
2024-04-28 08:16
Revenue and Profit - The company's revenue for Q1 2024 reached ¥7,442,979,521.58, representing a 10.17% increase compared to ¥6,756,081,779.54 in the same period last year[5] - Net profit attributable to shareholders was ¥75,533,309.91, up 11.51% from ¥67,734,160.88 year-on-year[5] - Total operating revenue for Q1 2024 reached ¥7,442,979,521.58, an increase of 10.14% compared to ¥6,756,081,779.54 in the same period last year[19] - Net profit for Q1 2024 was ¥117,353,880.03, representing a 20.19% increase from ¥97,598,224.23 in Q1 2023[19] - The total comprehensive income for Q1 2024 reached ¥117,353,880.03, representing a 20.2% increase from ¥97,598,224.23 in Q1 2023[20] - The net profit attributable to the parent company for Q1 2024 was ¥75,533,309.91, an increase of 11.8% compared to ¥67,734,160.88 in Q1 2023[20] - The net profit for minority shareholders was ¥41,820,570.12, up 40.0% from ¥29,864,063.35 in the previous year[20] Earnings Per Share - Basic and diluted earnings per share increased by 11.50% to ¥0.2589 from ¥0.2322[5] - Basic and diluted earnings per share for Q1 2024 were both ¥0.2589, compared to ¥0.2322 in Q1 2023, reflecting an increase of 11.6%[20] Cash Flow - The net cash flow from operating activities decreased significantly by 60.77%, amounting to ¥275,331,117.53 compared to ¥701,776,323.32 in the previous year[5] - Cash inflows from operating activities totaled ¥8,440,014,881.01, a rise of 8.2% from ¥7,801,946,286.47 in the previous year[22] - The company reported a total cash outflow from operating activities of ¥8,164,683,763.48, which is an increase of 15.0% compared to ¥7,100,169,963.15 in the previous year[22] - The net cash flow from financing activities was -¥226,598,554.56, worsening from -¥104,917,741.81 in the previous year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥16,082,498,905.81, down 6.06% from ¥17,120,851,592.43 at the end of the previous year[5] - Total liabilities decreased to ¥9,883,013,767.06 from ¥11,029,338,906.75, a reduction of 10.41%[17] - Cash and cash equivalents at the end of the period were ¥2,853,572,169.25, down from ¥2,885,462,449.66, a decrease of 1.10%[16] - Accounts receivable decreased to ¥7,942,072,887.18 from ¥8,421,185,110.43, a decline of 5.67%[16] - Inventory increased to ¥2,617,349,058.70 from ¥2,561,699,128.54, an increase of 2.17%[16] - The company reported a decrease in short-term borrowings to ¥3,084,063,485.60 from ¥3,787,853,711.27, a reduction of 18.54%[17] - The total equity increased to ¥6,199,485,138.75 from ¥6,091,512,685.68, reflecting a growth of 1.78%[17] Other Income and Expenses - Other income decreased by 35.72% to ¥6,436,318.52 compared to ¥10,013,086.82 in the previous period[9] - Investment income showed a significant change, with a profit of ¥239,798.53 compared to a loss of ¥236,767.93 in the previous year, marking a 201.28% increase[9] - The company reported a substantial increase in operating income, with other operating income rising by 3437.83% to ¥11,569,023.03 from ¥327,009.35[9] - Total operating costs for Q1 2024 were ¥7,289,981,773.84, up from ¥6,614,124,799.91, reflecting a year-over-year increase of 10.18%[19] Investment Activities - Cash flow from investment activities increased by 760.30% to ¥12,509,583.87 due to the disposal of subsidiaries[9] - In Q1 2024, the total cash outflow from investment activities decreased by 59.91% to ¥3,691,581.05, primarily due to reduced capital expenditures[10] - Cash inflow from investment activities increased significantly by 313.72% to ¥8,818,002.82, attributed to higher cash inflows from investment activities[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,943, with no preferred shareholders[12] - The largest shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of the shares, totaling 41,876,431 shares[12] - The second-largest shareholder, China Everbright Group Co., Ltd., holds 14.12% of the shares, totaling 41,180,805 shares[12] - The company reported a 67.59% decrease in cash received from minority shareholders' investments, totaling ¥9,450,000.00[10] - The company experienced a 149.63% increase in cash received from other financing activities, totaling ¥22,965,642.98, due to increased borrowings from minority shareholders[10]
嘉事堂:2023年社会责任报告
2024-04-28 08:14
嘉事堂药业股份有限公司 Cachet Pharmaceutical Co., Ltd (北京市海淀区昆明湖南路 11 号 1 号楼) 2023 年企业社会责任报告 股票代码:002462 股票简称:嘉事堂 - 关于本报告说明 1、报告简介:报告回顾了公司 2023 年在社会责任方面所做的各项工作,披 露了公司履行经济、环境和社会责任方面的理念、践行和成绩。 2、编写标准:本报告编制遵循《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》的规定。 3、时间范围:报告中的 2023 年指 2023 年 1 月 1 日-12 月 31 日,部分内容 适当追溯以往年份。 | 第一节 2023 年公司党建工作 4 | | --- | | 第二节 经营与发展综述 6 | | 第三节 内控管理 9 | | 第四节 企业责任 12 | | 第五节 社会公益 15 | | 第六节 总结与展望 17 | 第一节 2023 年公司党建工作 2023 年,是全面贯彻落实党的二十大精神开局之年,公司党委以习近平新 时代中国特色社会主义思想为引领,切实扛起全面从严治党主体责任,坚决把思 想和行动统一到党中央决策部署上 ...
嘉事堂:关于向银行申请2024年综合授信额度的公告
2024-04-28 08:14
股票代码:002462 股票简称:嘉事堂 公告编号:2024-15 嘉事堂药业股份有限公司 嘉事堂药业股份有限公司董事会 2024 年 4 月 29 日 单位:人民币亿元 | 序号 | 公司 | 汇总 | 光大 | 工商 | 交通 | 中国 | 浦发 | 广发 | 北京 | | 平安 杭州 | 北京 | 兴业 | 招商 | 上海 | 四川 江苏 | 民生 | 成都 | 天府 | 宁波 | 农业 | | 南京 中信 | 渤海 成都农 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 银行 | 银行 | 银行 | 银行 | 银行 | 银行 | 银行 | | 银行 银行 农商行 | | 银行 | 银行 | 银行 | 银行 银行 | 银行 | 银行 | 银行 | 银行 | 银行 | | 银行 银行 | 银行 商银行 | | 1 | 嘉事学药业股份有 ...
嘉事堂:2023年度独立董事述职报告(熊焰)
2024-04-28 08:14
嘉事堂药业股份有限公司 2023 年度独立董事述职报告 根据《上市公司独立董事管理办法》和《公司章程》的规定,作为嘉事堂药 业股份有限公司(以下简称"嘉事堂"或"公司")第七届董事会独立董事,现 将本人本年度履行独立董事职责情况述职如下: 2023 年,本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》 《深圳证券交易所股票上市规则》等法律、法规、规范性文件及《公司章程》、 《独立董事工作制度》等内部制度的规定和要求,勤勉尽责地履行独立董事的职 责和义务,审慎认真地行使公司和股东赋予的权利,积极参加股东大会、董事会 及专门委员会会议,维护公司整体利益,维护全体股东尤其是中小股东的合法权 益,并在深入了解公司情况的基础上,运用专业知识和经验履行职责,作为董事 会成员对公司重大事项进行决策,为公司发展提供意见和建议,有效发挥了独立 董事的作用。 一、独立董事的基本情况 熊焰,男,管理学硕士,曾任北京金融资产交易所有限公司董事长,现任北 京国富资本有限公司董事长。 报告期内,本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求,不存在影响独立性的情形。 二、独立董事年度履职情况 (一)出席会议 ...
嘉事堂:关于变更公司职工代表监事的公告
2024-04-28 08:14
证券代码:002462 证券简称:嘉事堂 公告编号:2024-21 嘉事堂药业股份有限公司 关于公司变更职工代表监事的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整,没有虚假记载、误导性陈述或重大遗漏。 特此公告。 嘉事堂药业股份有限公司监事会 2024 年 4 月 29 日 附:职工代表监事简历 张洁女士简历 张洁,女,汉族,北京人,1988 年 3 月出生,大学学历,经济学学士,中共 党员,2018 年 7 月入职嘉事堂,现为嘉事堂党群工作部/巡察办公室/团委经理 助理。 截至目前,张洁女士不持有公司股份,与持有公司 5%以上股份的股东、实际 控制人、公司其他董事、监事、高级管理人员无关联关系,不存在《公司法》第 一百四十六条规定的情形之一,未被中国证监会采取证券市场禁入措施,最近三 年未受到中国证监会的行政处罚,最近三年未受到深圳证券交易所的公开谴责或 通报批评,亦不存在被深圳证券交易所认定不适合担任公司监事的情形,不存在 因涉嫌犯罪被司法机关立案侦查或者涉嫌违法违规被中国证监会立案调查的情 形,未曾被中国证监会在证券期货市场违法失信信息公开查询平台公示或者被人 民法院纳入失信被执行人 ...
嘉事堂:2023年度独立董事述职报告(张海燕)
2024-04-28 08:14
嘉事堂药业股份有限公司 2023 年度独立董事述职报告 根据《上市公司独立董事管理办法》和《公司章程》的规定,作为嘉事堂药 业股份有限公司(以下简称"嘉事堂"或"公司")第七届董事会独立董事,现 将本人本年度履行独立董事职责情况述职如下: 2023 年,本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》 《深圳证券交易所股票上市规则》等法律、法规、规范性文件及《公司章程》、 《独立董事工作制度》等内部制度的规定和要求,勤勉尽责地履行独立董事的职 责和义务,审慎认真地行使公司和股东赋予的权利,积极参加股东大会、董事会 及专门委员会会议,维护公司整体利益,维护全体股东尤其是中小股东的合法权 益,并在深入了解公司情况的基础上,运用专业知识和经验履行职责,作为董事 会成员对公司重大事项进行决策,为公司发展提供意见和建议,有效发挥了独立 董事的作用。 一、独立董事的基本情况 张海燕,女,会计学博士,现任清华大学经济管理会计系副教授,兼任中汽 研汽车试验场股份有限公司、广州安凯微电子股份有限公司独立董事。 报告期内,本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求,不存在影响独立性的情形。 二、 ...